PepGen Inc.

Healthcare · Biotechnology · United States

Last price 2.41 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 166.92M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Bo...